Adaptimmune Ther Ads (ADAP) 7.12 $ADAP Adaptimmune

New Post Public Reply Private Reply Replies (0) Message Board

Sep 24, 2016 at 3:05 AM

Adaptimmune Ther Ads (ADAP) 7.12 $ADAP

Adaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR(R) T-cell Therapies Towards Commercialization
GlobeNewswire - Mon Sep 19, 6:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a new five-year strategic manufacturing agreement with PCT, a Caladrius company, ("PCT"

a subsidiary of Caladrius Biosciences (Nasdaq:CLBS) for the supply of Adaptimmune's SPEAR(R) T-cell therapies. Under the contract, Adaptimmune will benefit from exclusive access to an EU and FDA compliant manufacturing unit at PCT as well as dedicated, specialist staff.
ADAP: 7.12 (unch), CLBS: 4.88 (+0.25)

Caladrius Subsidiary, PCT, Announces Five-Year Strategic Manufacturing Services Agreement with Adaptimmune
GlobeNewswire - Mon Sep 19, 6:30AM CDT
Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"

, a cell therapy company combining an industry-leading development and manufacturing services provider (PCT, LLC, A Caladrius Company or "PCT"

with a select therapeutic development pipeline, today announces a new five-year strategic manufacturing services agreement under which PCT will produce SPEAR(R) T-cell therapies for Adaptimmune Therapeutics plc (NASDAQ:ADAP) ("Adaptimmune"

. PCT, through dedicated, specialized staff and facilities, will produce the SPEAR(R) T-cell products at its Allendale, New Jersey facility in a manner compliant with both U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulations.
ADAP: 7.12 (unch), CLBS: 4.88 (+0.25)

Adaptimmune to Participate in Two Upcoming Investor Conferences
GlobeNewswire - Thu Sep 08, 2:30PM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the following two September conferences:
ADAP: 7.12 (unch), MS: 31.91 (-0.33)

Adaptimmune Reports Second Quarter 2016 Financial Results
Globe Newswire - Mon Aug 08, 6:00AM CDT
- Conference call to be held today at 8:00 AM ET (1:00 PM BST) -
ADAP: 7.12 (unch)

Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR(R) T-cell Therapy in Myxoid Round Cell Liposarcoma
GlobeNewswire - Wed Aug 03, 3:23PM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that it has received notice from the U.S. Food and Drug administration that a partial clinical hold has been placed on its planned pivotal study of NY-ESO SPEAR(R) T-cell therapy in myxoid round cell liposarcoma (MRCLS). This trial is not yet active at any investigational sites, and has not recruited any patients. This notification of partial clinical hold does not apply to any other Adaptimmune study.
ADAP: 7.12 (unch)

Adaptimmune to Report Second Quarter 2016 Financial Results on August 8, 2016
GlobeNewswire - Tue Aug 02, 7:15AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended June 30, 2016 before the open of the U.S. markets on Monday August 8, 2016. Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. Eastern Time (1:00 p.m. BST) on the same day at which time management will provide a business update and discuss the financial results for the second quarter of 2016.
ADAP: 7.12 (unch)

ADAP: a Biotech Stock Using T-Cell Immunotherapy to Treat Cancer
Maher Syed - Zacks Investment Research - Mon Aug 01, 5:13PM CDT
Here's why Adaptimmune therapeutics looks like an intriguing investment prospect right now.
ADAP: 7.12 (unch), GSK: 43.42 (-0.16)

Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR(R) T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
Globe Newswire - Thu Jul 28, 10:33AM CDT
New Initiative Provides Access to Scientific Advice and Supports Accelerated Assessment for Therapies Targeting Unmet Medical Needs
ADAP: 7.12 (unch)

Adaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific's Dynabeads(TM) CD3/CD28 Cell Therapy System
GlobeNewswire - Tue Jun 21, 6:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a commercial development and supply agreement with Thermo Fisher Scientific. The new 10-year agreement augments Adaptimmune's exclusive license and supply relationship with Thermo Fisher for the Dynabeads CD3/CD28 Cell Therapy System (CTS(TM))* for use in the manufacture of Adaptimmune's SPEAR(TM) T-cell therapies.
ADAP: 7.12 (unch)

Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR(TM) T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting
GlobeNewswire - Sun Jun 05, 8:05AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a poster presentation of updated data on its lead clinical program, an affinity enhanced SPEAR(TM) T-cell receptor therapy targeting the NY-ESO-1 cancer antigen, in patients with advanced tumors at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting.
ADAP: 7.12 (unch)

Adaptimmune to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 10:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 4:30 PM EDT (9:30 PM BST). The conference is being held at the Grand Hyatt in New York.
ADAP: 7.12 (unch)

Adaptimmune Announces Succession Plan for Chairman at End of 2016
GlobeNewswire - Tue May 24, 6:32AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP) ("Adaptimmune" or the "Company"

, a leader in T-cell therapy to treat cancer, today announced a succession plan for the Chairmanship position that will take effect at the end of 2016.
ADAP: 7.12 (unch)

Adaptimmune Strengthens Board with Appointment of Barbara Duncan
GlobeNewswire - Tue May 24, 6:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP) ("Adaptimmune" or the "Company"

, a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent Non-Executive Director effective from June 23, 2016. Ms. Duncan will also serve as a member of the Audit Committee.
MDGN: 5.54 (+0.16), ICPT: 166.23 (-4.24), ADAP: 7.12 (unch)

Adaptimmune to Present at the 2016 UBS Global Healthcare Conference
GlobeNewswire - Thu May 19, 8:00AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 10:30 AM EDT (3:30 PM BST). The conference is being held at the Grand Hyatt in New York.
ADAP: 7.12 (unch)

Pfizer (PFE) Reveals Positive Phase III Data on Trumenba
Zacks Equity Research - Zacks Investment Research - Mon May 16, 9:03AM CDT
Pfizer (PFE) announced positive data from two phase III studies on Trumenba for providing protection against serogroup B meningococcal disease.
ANIP: 66.64 (-0.17), PFE: 34.26 (+0.11), ADAP: 7.12 (unch), BMY: 56.48 (+0.06)

New Strong Buy Stocks for May 13th
Zacks Equity Research - Zacks Investment Research - Fri May 13, 12:03PM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday.
CABO: 578.73 (+1.70), ADAP: 7.12 (unch), DF: 16.50 (-0.11), BBL: 28.49 (-0.11), PAC: 90.70 (-0.38)

Bayer Stops Phase II Adempas Study Due to Safety Issues
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:33AM CDT
Bayer (BAYRY) has terminated a phase II study on Adempas in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias, with immediate effect.
ANIP: 66.64 (-0.17), ADAP: 7.12 (unch), BMY: 56.48 (+0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lavazza 2027 Calendar: Moments of Pleasure Worldwide

Capturing Fleeting Joy Through the Lens In 2027, Lavazza sets the stage for an evocative exploration of human pleasure through its iconic calendar. Teaming up with photographers Jim Goldberg, Alex Majoli, and Paolo Pellegrin, the project spans three vibrant cities: New York, Lisbon, and Hong Kong. These masters of the lens invite us to pause and appreciate the understated...

Endava Faces Class Action: Investor Reactions and Next Steps

Trouble at Endava: Leadership Shakeup and Financial Concerns So, here's the kicker—Endava's got itself into one mighty mess worth chewing over with your morning coffee. When your top brass drops like flies, and you're fumbling your financials, investors start sweating bullets. On October 28, 2026, Endava plc (NYSE: DAVA) confesses to some serious accounting missteps....

Eve Air Mobility's Vector System Proves Its Worth

Eve Air Mobility's Vector system just pulled off something impressive at the Interlagos Circuit, showing it's not just a buzzword in the urban air mobility sphere. Picture this—over 100 helicopter flights in a day, all managed smoothly during one of the biggest motorsport events. That's the kind of action that gets investors to sit up and take notice of NYSE:EVEX....

Toronto's Distillery Winter Village Kicks Off 2026

Toronto's Holiday Spirit Ignites Toronto just cranked up the holiday spirit with the lighting of a 55-foot Christmas tree at The Distillery Winter Village. Let me tell you, it's a sight that could warm your innards on the coldest winter night. Presented by Quince, this winter wonderland opened its doors for 2026—and it's looking like they're pulling out all the stops...

New Senior Care Location Opens in Broward County

A Personal Mission Driving Business in Hollywood Dive deep into any community, and you'll often find stories that tug at the heartstrings—especially when they're about family. That's the case with Saudia Sital, a Broward County local who's just opened Always Best Care Senior Services in Hollywood, Florida. Her journey from personal caregiver to business owner isn't just...

Hebrew Learning Made Simple: Expert's Structured Guide

Cracking the Hebrew Code: A Balanced Guide Ever tried staring down a new language script and felt like you were on a sinking ship? That’s where a lot of folks starting off with Hebrew reading find themselves. It's no sunny stroll through a Greek alphabet park—Hebrew's a whole different ballgame. But Diana Yacobi from Sarah & David’s Read Hebrew Now offers a roadmap...

MV Transportation Celebrates Leadership Nomination for FTA

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Dana-Farber Integrates IconPCR for Precise cfDNA Sequencing

Innovating Precision in cfDNA Sequencing One day you're trudging along old paths, and the next, technology throws you a curveball that's too critical to ignore. That's the scene at Dana-Farber Cancer Institute with their latest lab upgrade. They've bent the knee to integrate n6's iconPCR system into their toolkit for liquid biopsy research—a move that's caught my...

Sports Clock Radio: A Game Time Enthusiast's Dream

A New Gadget for the Diehard Fan Fanatics, gather 'round. There's an innovation rolling out that's looking to marry the good old alarm clock radio with the rush of game day fever! Over in Pittsburgh, an inventor's cooking up something that every loyal sports fan might soon find irresistible—a Sports Clock Radio, bringing the stadium experience to your living room or...

Cuisine.K Brings Korean Seafood to Seattle Spotlight

Korean Seafood Makes Waves in Seattle Bring out the chopsticks, ‘cause Korean seafood just took Seattle by storm with the Cuisine.K Korean culinary showcase. Hosted by CJ Foods, alongside the Korea Fisheries Association, this event smacked the local food scene square in the face with the unique flavors and techniques of K-Seafood—from students all the way to seasoned...